Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12303610 | 0.87 | SCN9A (0.48) | SCN9AFPR2RAB9AALDH1A1MAPT | |
| SCHEMBL12303690 | 0.86 | TDP1 (0.49) | SCN9AFPR2ALDH1A1MAPTATM | |
| SCHEMBL12303601 | 0.82 | FPR2 (0.45) | SCN9AFPR2RAB9AALDH1A1MAPT | |
| SCHEMBL11922573 | 0.77 | CFTR (0.51) | SCN9AFPR2ALDH1A1MAPTATM | |
| SCHEMBL12303615 | 0.76 | KCNH2 (0.51) | SCN9AFPR2RAB9ADRD1KCNH2 | |
| SCHEMBL12303836 | 0.75 | KDM4E (0.48) | SCN9AFPR2KCNH2MAPK10 | |
| SCHEMBL4318313 | 0.73 | ALDH1A1 (0.54) | SCN9AFPR2ALDH1A1MAPTATM | |
| SCHEMBL30678410 | 0.73 | RAB9A (0.70) | RAB9AALDH1A1DRD1 | |
| SCHEMBL12303339 | 0.73 | HDAC3 (0.46) | MAPK10 | |
| SCHEMBL11187255 | 0.72 | ALDH1A1 (0.59) | SCN9AFPR2ALDH1A1MAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230465-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110230465-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| WO-2011032277-A1 | QUINAZOLINONE DERIVATIVES AS VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230465-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2E | SCN9A 2265/4885FPR2 2994/4885RAB9A 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.